Over a career spanning 20 years, Nasir has had varied roles in the pharmaceutical industry, in academia and as a regulator with MHRA. He has participated in five high-tech/biotech start-ups either as a co-founder or as an early stage employee.
Currently, at the Medicines and Healthcare Regulatory Agency (MHRA), he is the resident expert in the pharmaceutical assessment of paediatric medicines, evaluating Paediatric Investigation Plans (PIPs) and Paediatric Use Only Medicines (PUMAs). He is also drafting the European Medical Agency's Reflection Paper on the Quality Aspects of Medicines for Older People.
In late 2013, he was also appointed by the MHRA as the representative for the acad...
We鈥檝e updated our privacy policy so that we are compliant with changing global privacy regulations and to provide you with insight into the limited ways in which we use your data.
You can read the details below. By accepting, you agree to the updated privacy policy.
